Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refractory Prostate Cancer

Ascenta Therapeutics announced positive preliminary results from its Phase II study of AT-101 in combination with docetaxel and prednisone (D/P) in men with docetaxel refractory, castrate resistant prostate cancer (CRPC) at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, FL.

More: continued here

Filed under: Prostate on March 11th, 2009